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Background: Measurements of CFTR function in rectal biopsies ex vivo have been used for diagnosis and prognosis of
Cystic Fibrosis (CF) disease. Here, we aimed to evaluate this procedure regarding: i) viability of the rectal specimens
obtained by biopsy forceps for ex vivo bioelectrical and biochemical laboratory analyses; and ii) overall assessment
(comfort, invasiveness, pain, sedation requirement, etc.) of the rectal forceps biopsy procedure from the patients
perspective to assess its feasibility as an outcome measure in clinical trials.
Methods: We compared three bowel preparation solutions (NaCl 0.9%, glycerol 12%, mannitol), and two biopsy forceps
(standard and jumbo) in 580 rectal specimens from 132 individuals (CF and non-CF). Assessment of the overall rectal
biopsy procedure (obtained by biopsy forceps) by patients was carried out by telephone surveys to 75 individuals who
underwent the sigmoidoscopy procedure.
Results: Integrity and friability of the tissue specimens correlate with their transepithelial resistance (r =−0.438 and −0.305,
respectively) and are influenced by the bowel preparation solution and biopsy forceps used, being NaCl and jumbo
forceps the most compatible methods with the electrophysiological analysis. The great majority of the individuals (76%)
did not report major discomfort due to the short procedure time (max 15 min) and considered it relatively painless (79%).
Importantly, most (88%) accept repeating it at least for one more time and 53% for more than 4 times.
Conclusions: Obtaining rectal biopsies with a flexible endoscope and jumbo forceps after bowel preparation with NaCl
solution is a safe procedure that can be adopted for both adults and children of any age, yielding viable specimens for
CFTR bioelectrical/biochemical analyses. The procedure is well tolerated by patients, demonstrating its feasibility as an
outcome measure in clinical trials.
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reproduction in any medium, provided the orchannel expressed at the apical membrane of epithelial
cells, a major regulator of salt and water transport in epi-
thelia [1]. CF is dominated by respiratory disease but other
organs are also affected including the pancreas, intestine
and sweat gland as well as male reproductive tract [2].
Although the clinical diagnosis of classic (severe)
forms of CF is straightforward, for other patients there
is wide variability in the clinical presentation and
organ involvement, thus making the CF diagnosis more
challenging [3-7]. Moreover, increasing numbers of
asymptomatic patients are currently identified through
extended programs of CF newborn screening [4,8-11].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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parameters used for the diagnosis and prognosis of CF,
is ex vivo assessment of CFTR-mediated Cl- secretion
channel in freshly collected rectal biopsies [8,9,12-19].
Moreover, ongoing clinical trials of novel therapeutic
CFTR-modulators require improved and robust bio-
markers to adequately assess their in vivo efficacy on
CFTR. Indeed, there is also great potential to exploit this
method to pre-clinically assess compound efficacy dir-
ectly on human tissues ex vivo, as we previously showed
[20] or as a biomarker in clinical trials of novel CFTR-
modulators [21-23]. Moreover, it may even be used to
evaluate patient/CFTR genotype responsiveness to a
drug through a personalized-medicine approach.
For such disseminated usage of this method, standard-
ized operational procedures (SOP) for bowel preparation
and biopsing are essential to ensure good tissue viability
for the quantitative assessment of the bioelectric param-
eters [13]. Moreover, since the procedure involves
biopsing, a somewhat invasive procedure possibly trig-
gering psychological rejection, there should be clear
information on how it is perceived from the patients’
perspective (comfort, invasiveness, pain, sedation re-
quirement, etc.) to obtain an overall assessment of
the method.
Our two-fold aim of the present study was: a) to
evaluate the technical procedure regarding the quality
for bioelectrical/biochemical laboratory analyses of 580
rectal specimens from 132 individuals (CF and non-CF),
namely by comparing different bowel preparations and
different biopsy forceps sizes as well as regarding the
safety of the procedure to the patient; and b) to deter-
mine individuals’ assessment regarding the rectal biopsy
procedure feasibility to be possibly used as an outcome
measure in clinical trials, as successfully described in
other studies [24,25].
Our results demonstrate that best tissue viability for
Ussing chamber measurements results after bowel
preparation with isotonic solution (NaCl 0.9%) and
usage of jumbo (vs standard size) biopsy forceps al-
lowing collection of larger specimens without dis-
rupting tissue integrity. Obtaining rectal biopsies with
a flexible endoscope and jumbo forceps is also shown
here to be a safe procedure for use in both children
and adults (age range was 6 months to 52 years). Data
collected on patient’s comfort show that the great ma-
jority of individuals (76%) did not report major dis-
comfort due to the short procedure time (max 15 min)
and considered it relatively painless (79%), regardless
of sedation. Moreover, most individuals accept repeat-
ing the procedure for at least one more time (88%) and
53% for more than 4 times, supporting the feasibility
of the current approach as an outcome measure in
clinical trials.Methods
Subjects
Access to human tissues used in this study received
approval from the Research Ethics Committee of the
Faculty of Medical Sciences, State University of Campinas
(Unicamp, ref. 503/2007), in accordance with the
Helsinki Declaration of the World Medical Associ-
ation. Signed informed consent was obtained from all
individuals (or parents/tutors, for those <18 yrs).
Altogether, 580 freshly excised rectal biopsies were
analysed at Unicamp from 132 individuals, including
CF patients (n = 67) with previously established diag-
nosis [14] (genotypes in Additional file 1: Table S6 and
in Sousa et al [14]) and age-matched non-CF individ-
uals (n = 65) undergoing biopsing for other clinical rea-
sons and agreeing to participate in the study (Figure 1).
The number of biopsies found suitable for quantitative
bioelectrical measurements was 404 (i.e., ~70%). As-
sessment of the overall rectal biopsy procedure by pa-
tients was carried out by telephone surveys to
individuals (n = 75) who underwent the sigmoidos-
copy/rectal forceps biopsy procedure (Figure 1).Bowel preparation
Bowel preparation was done on-site (~30 min prior to
sigmoidoscopy) by applying an enema of i) saline solu-
tion (0.9% NaCl, total volume: 0.25-1 L); or ii) glycerin-
ated solution (12% glycerol in distilled water, total
volume: 0.25-1 L), for individuals undergoing sigmoidos-
copy; or iii) oral mannitol solution (20%, total volume:
0.5 L on the previous day) for individuals undergoing
colonoscopy (Figure 1). Satisfactory bowel cleaning was
achieved in 99.24% (131/132) of cases. At our endoscopy
unit, oral mannitol is used only when a complete
cleaning of the bowel is required; while the routine so-
lutions used for sigmoidoscopy are usually glycerinated
solution or saline solution. These solutions are cheap
and offer low risk of dehydration for the patient (espe-
cially for people that live in very hot climates, like
Brazil). Also in the case of rectal biopsies, only the
rectum needs to be cleaned, so performing a quick
enema on-site prior to the procedure is adequate and
also more comfortable for the patient.Rectal biopsy procedure
Superficial 4–6 rectal mucosa specimens (2–4 mm
diameter-Ø) were obtained by colon forceps with visual
examination (Figure 1), avoiding the risk of bleeding,
perforation or tissue damage, and immediately stored in
ice-cold RPMI1640 with 5% (v/v) Fetal Bovine Serum
(FBS). The procedure was performed in 3–15 min by ex-
perienced paediatric gastro-endoscopists assisted by a
Figure 1 Flow-chart of the technical biopsing aspects assessed in the present study. Bioelectrical measurements were performed for rectal
biopsies (n = 580) from all the individuals enrolled in the study (n = 132) to assess tissue viability [14]. Bowel preparation included enemas of
either NaCl 0.9%, glycerol 12% (v/v) or oral mannitol 20% (w/v) solutions. Two different biopsy forceps were tested, namely jumbo (3.4 mm Ø)
and standard (2.5 mm Ø), independently of bowel preparation. Macroscopic and histologic evaluation of rectal biopsies was achieved for 107 and
78 individuals, respectively. Patient assessment surveys were carried out for 75 individuals undergoing sigmoidoscopy with rectal biopsy
collection by biopsy forceps, divided into 4 age groups, namely (yrs): 0–9; 10–9; 20–29; ≥30.
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Additional file 3: video S1 - Rectal biopsy procedure).
We aimed to compare different biopsy forceps, as suc-
tion biopsies are not in current use at our endoscopy
unit. In a first stage, we used the Olympus® 2.5 mm
forceps (standard-oval without needle; required work
channel size: 2.8 mm Ø; Shinjuku, Tokyo, Japan) and in
a second stage the Endoflex® 3.4 mm (jumbo-oval
without needle; required work channel size: 3.7 mm Ø;
Voerde, Germany) in order to obtain larger specimens,
optimizing the adequacy of the specimens for functional
and biochemical studies.
Sedation
From the 132 individuals enrolled in this study, 63
performed endoscopic procedures under sedation and
69 without. Intravenous sedation with midazolam (asso-
ciated or not with meperidine) was performed for all
individuals undergoing colonoscopy (n = 28) for other
reasons than the rectal biopsy procedure (these were all
non-CF individuals).
Sigmoidoscopy was done with or without sedation
depending if the individual was already performing other
procedures (like gastrostomy or upper endoscopy,
n = 10) or depending on individuals’ will, collaboration
or anxiety (n = 25, i.e., only 24% of the patients undergo-
ing sigmoidoscopy preferred to be sedated). For children
under 9 years old, the parents together with the paediat-
ric gastro-endoscopists decided whether it was preferable
to have sedation; while the individuals above 10 years old
could choose to have sedation or not by themselves,because they had already a better understanding of the
overall procedure. For those 35 individuals, sedation
was performed as follows: a) intravenous sedation
with midazolam (n = 9); b) intravenous anaesthesia
with propofol (n = 2); c) intravenous anaesthesia with
propofol + alfentanil (n = 5); d) sevoflurane (with ni-
trous oxide 1:1) inhalation (n = 8); and e) intravenous
anaesthesia with propofol + sevoflurane inhalation
(n = 11). In general, individuals were monitored for
blood pressure, pulse, oxygen saturation and ECG
tracing by an anaesthologist. Children could also
choose if they wanted their parents with them during
the procedure or not.Macroscopic evaluation
Prior to mounting in Ussing chamber, tissues were
macroscopically evaluated regarding bleeding, mucus,
biopsy thickness (presence of submucosa or not), and
also for friability (tissue breakdown from manipulation),
in a scale from 0 to 3 (from absence to clear presence of
the descriptor), by two different technicians who were
blinded for the individual condition (CF/non-CF), bowel
preparation method and biopsy forceps used (Figure 1).
Regarding tissue integrity resulting from the biopsing
procedure, the scale was inverted to facilitate the techni-
cians’ evaluation, i.e., 0 means full integrity of the speci-
men while 3 means that the tissue is fully disrupted
(i.e. integrity is not present). Data on specimens’ macro-
scopic evaluation were obtained for 107 individuals and
was averaged for 2–5 biopsies/individual to obtain a
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lations and tables presented here.
Histology preparations
One out of the 4–6 rectal specimens collected per indi-
vidual was fixed in 4% formaldehyde, embedded in par-
affin and cut in thin sections (2–3 μM) for histological
observation and data were obtained for 78 individuals.
Sections were then deparaffinized dehydrated in xylene
(twice, 10 min), re-hydrated with absolute ethanol
(twice, 5 min), 95% ethanol (2 min), 70% ethanol (2) min
and briefly rinsed with distilled water and stained with
hematoxylin-eosin (HE) and Tricome’s Masson as previ-
ously [26]. Slides were mounted with xylene-based
mounting medium. Again, pathologists assessed speci-
mens blindly as above and data was obtained for 78
individuals.
Ussing chamber measurements
Tissues were equilibrated in the micro-Ussing chambers
for 30 min in perfused Ringer solution (in mmol/L: NaCl
145, KH2PO4 0.4, K2HPO4 1.6, D-glucose 5, MgCl2 1,
Ca2+-gluconate 1.3, pH 7.40, at 37°C) as previously
described [12-14]. Measurements of basal Rte were used
to assess tissue viability, after appropriate correction for
fluid resistance (Additional file 2: Ussing chamber mea-
surements and mounting of the tissue.).
Biochemical assays: immunoblotting and
immunofluorescence
Western blots were probed with a mixture (1:2000 dilution)
of two monoclonal anti-CFTR antibodies, M3A7 and
MM13-4 (Chemicon®, Millipore, Darmstadt, Germany) rec-
ognizing distinct epitopes to increase sensitivity as CFTR
has low expression levels in native tissues [27,28]. Total
protein extract (70 μg) was applied on the gel (Additional
file 2: Biochemical assays; immunoblotting and immuno-
fluorescence). For immunofluorescence tissue cryo-sections
were incubated with monoclonal anti-CFTR antibody 570
(CFF, USA) and secondary polyclonal Alexa 488 anti-
mouse antibody (Invitrogen, Carlsbad, CA, USA).
Questionnaire used for patients’ assessment of the rectal
biopsy procedure
Individuals were approached by telephone by two re-
searchers that did not have contact with the rectal bi-
opsy procedure to evaluate the overall procedure from
bowel preparation to collection of the biopsy (Additional
file 1, Figure S1, Additional file 2: Questionnaire used
for patients’ assessment of the rectal biopsy procedure).
Data were obtained for 75 individuals divided into 4 age
groups, namely (yrs): 0–9 (n = 21); 10–19 (n = 33);
20–29 (n = 7); ≥30 (n = 14). Most patients were children
(median age = 13 yrs). For children under 9 years old,the parents were asked to answer the questions as these
children are very young to fully understand the proced-
ure; while the individuals above 10 years old gave the re-
sponses themselves. Individuals were asked to rate the
discomfort in comparison to other procedures such as
nasal potential difference (NPD), nasal brushing, spirom-
etry, sweat test, bronchoscopy and blood collection. All
subjects enquired had undergone at least blood draws
and sweat-Cl- testing for comparison with rectal biopsy
(answers reported as “not applicable” were referred to
individuals that were not able to establish a clear com-
parison, because they did not remind very clearly these
procedures). They were also asked to comment on how
many times they would accept repeating the procedure
(Additional file 1: Figure S1, Additional file 2: Question-
naire used for patients’ assessment of the rectal biopsy
procedure).
Statistics
Statistical analyses were performed with SPSS software
(v.19; SPSS Inc, Chicago, IL, USA) and a p value < 0.05
was considered as statistically significant. Unless other-
wise stated, data are shown as mean ± SEM (n = number
of individuals studied). Pearson coefficients (r) were used
to find correlations and partial correlations between de-
scriptors for macroscopic evaluation and Rte of biopsies.
ANOVA, with Bonferroni post hoc correction when ap-
propriated, was used to find differences between groups’
means with a 90% confidence interval. For Crosstabs
regarding patients questionnaires, Pearson’s Chi-Square
tests were used to determinate independence among vari-
ables analysed. Monte Carlo estimates of the exact p-value
are provided whenever the data are too sparse or unbal-
anced for the asymptotic results to be reliable.Results
A flow-chart summarizing the technical biopsing aspects
assessed in the present study is shown in Figure 1.
Bowel preparation and biopsy forceps
The bowel cleaning procedures, consisting in administra-
tion of an oral laxative (for colonoscopy) or by enema (for
sigmoidoscopy) allowed equally good visualization of the
rectal mucosa and forceps during the sigmoidoscopy/
colonoscopy procedure. Expectedly, jumbo biopsy for-
ceps (3.4 mm Ø) generated larger specimens than
standard forceps (2.5 mm Ø), thus facilitating the
mounting of the tissue in Ussing chamber inserts.
Data referring to bowel preparation (Table 1, Additional
file 1: Table S1) show that there are statistically significant
differences (p = 0.054, 90% confidence interval) for tissue
integrity between the preparations using NaCl 0.9% (1.19 ±
0.12) and glycerol 12% (1.82 ± 0.21). Oral mannitol was not
Table 1 Summary of macroscopic evaluation data and bioelectrical measurements (Rte) of rectal biopsies vs. bowel
preparation and biopsy forceps
Bowel Preparation NaCl 0.9% Glycerol 12% Mannitol 20%
Biopsy Forceps Jumbo Standard Jumbo Standard Jumbo Standard
Tissue integrity 1.00 ± 0.11 2.00 ± 0.35 1.48 ± 0.31 2.21 ± 0.23 1.02 ± 0.02 1.97 ± 0.30
Friability 1.23 ± 0.12 1.36 ± 0.24 1.50 ± 0.31 1.81 ± 0.22 1.13 ± 0.33 1.33 ± 0.25
Bleeding 1.01 ± 0.08 1.21 ± 0.18 1.27 ± 0.21 1.16 ± 0.29 1.05 ± 0.22 0.83 ± 0.32
Mucus 1.12 ± 0.11 1.18 ± 0.17 0.91 ± 0.24 0.88 ± 0.13 0.74 ± 0.13 1.06 ± 0.13
Sub-mucosa (n) Yes 16 3 3 1 2 1
No 42 9 4 4 12 10
Rte (Ω.cm
2) 21.82 ± 1.03 14.37 ± 1.21 18.75 ± 2.66 13.57 ± 2.70 18.69 ± 0.98 13.32 ± 1.11
NOTE: Results are mean ± SEM; n = 107.
Table 2 Summary of the correlations and partial
correlations (by bowel preparation and biopsy forceps)
between tissue transepithelial resistance (Rte) and
macroscopic evaluation of biopsies
Transepithelial resistance (Rte)
Pearson (r) p-value
Tissue integrity −0.438 8.51 x 10-5
-4
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the biopsy forceps used (Table 1).
Regarding biopsy forceps, mean values for tissue integ-
rity (Jumbo = 1.07 ± 0.09 vs Standard = 2.04 ± 0.18) and
also for Rte (Jumbo = 20.97 ± 0.81 Ω.cm
2 vs Standard =
14.01 ± 0.86 Ω.cm2) are statistically different between
the forceps used (p = 5.51x10-7 for tissue integrity and
p = 8.42x10-8 for Rte, Table 1, Additional file 1: Table
S2). Friability (i.e. tissue susceptibility to breakdown with
manipulation) is the only parameter significantly affected
by the presence of sub-mucosa (Additional file 1: Table
S3, p = 0.008), but this may result from more tissue ma-
nipulation being required to remove the sub-mucosa.
Regarding bleeding and mucus, their presence/abun-
dance were not influenced by bowel preparation nor bi-
opsy forceps (Table 1).
In addition, we also found statistically significant cor-
relations (Table 2, Figure 2) between Rte and tissue in-
tegrity (r = −0.438, p = 8.51x10-5) and between Rte and
friability (r = −0.305, p = 6.65x10-3), which is supported
by partial correlations with bowel preparation and
biopsy forceps. Data concerning presence/abundance
of blood and mucus do not correlate with tissue
viability-Rte (Table 2, Figure 2). We found no influence
by usage of sedation in the procedure regarding tissue
viability (Additional file 1: Table S4).Bowel preparation −0.403 3.74 x 10
Biopsy forceps −0.244 0.036
Friability −0.305 6.65 x 10-3
Bowel preparation −0.301 7.88 x 10-3
Biopsy forceps −0.277 0.015
Bleeding −0.176 0.110
Bowel preparation −0.185 0.093
Biopsy forceps −0.182 0.100
Mucus +0.078 0.507
Bowel preparation +0.032 0.787
Biopsy forceps +0.115 0.330
NOTE: Pearson (r) and p-values indicating significant correlations are
highlighted (n = 107).Histological and macroscopic evaluation of rectal tissues
and biochemical analysis
Histological examination of rectal specimens revealed no
obvious abnormalities and only some inflammatory cells
were found, independently of both tissue origin (CF or
non-CF) or bowel preparation (Figure 3A).
Tissues were evaluated for integrity, friability, bleed-
ing, mucus, and thickness of biopsy (presence of
sub-mucosa or not) under a dissecting microscope by
two different technicians in blinded way (Table 1). As
shown above, the scores obtained from this evaluation
were correlated with bowel preparation, biopsy forcepsand measurements of transepithelial resistance (Rte) to
assess tissue viability (Table 2).
We have also used these native colonic tissues to
further look at maturation pattern and localization of
wt- and mutant-CFTR protein, which can serve as a
valuable tool to evaluate the effects of CFTR-modulators
together with Ussing chamber measurements of CFTR-
mediated Cl- secretion. As shown in Figure 3B, we were
able to detect CFTR protein at the plasma membrane
for both wt-CFTR and F508del/P205S-CFTR (P205S is
a class IV mutation), but F508del/F508del-CFTR was
retained into cytoplasm, close to the basolateral mem-
brane. These findings were in accordance with the mat-
uration pattern of CFTR protein (Figure 3C), which was
found to be fully-glycosylated (presence of band C) for
wt-CFTR and another class IV CFTR-mutant (R334W),
Figure 2 Correlations between tissue transepithelial resistance (Rte) and macroscopic descriptors (tissue integrity, friability, bleeding
and mucus) according to A) biopsy forceps and B) bowel preparation (n = 107 individuals).
Servidoni et al. BMC Gastroenterology 2013, 13:91 Page 6 of 12
http://www.biomedcentral.com/1471-230X/13/91but failed to mature in the biopsy from a F508del/F508del
patient.Patient safety and comfort with overall procedure
No major complications (perforation, haemorrhage) were
reported following NaCl 0.9% bowel preparation or jumbo
biopsy forceps (allowing larger and more viable rectal speci-
mens, 353 biopsies performed in total), thus making this a
safe procedure. There was only one CF patient complaining
about abdominal pain who was observed for 4 h after the
procedure, but had no other complications and recovered
by then from such pain. We also report other minorcomplications that cannot be fully related to the sigmoidos-
copy procedure, (see Discussion).
Patients were asked by telephone to assess the rectal
biopsy procedure by posing several questions targeting
several aspects of patient assessment (Figure S1). The
questions were divided into 3 broad categories (Additional
file 2: Questionnaire used for patients’ assessment of the
rectal biopsy procedure): i) procedural pain/discomfort and
sedation requirement (questions 1,2,3,5); ii) comparison
with other clinical/diagnosis procedures (question 4); and
iii) acceptance towards the possible introduction of this
method as an outcome measure in clinical trials (question
7). In addition, there was also a question regarding
Figure 3 Histological and macroscopic evaluation of rectal tissues and biochemical analysis. A) Rectal biopsies (longitudinal cuts) were
histologically evaluated by Hematoxilin-Eosin (HE) and Masson’s Tricome stainings in non-CF and CF tissues. Images show healthy epithelia, with
no fibrotic processes and only some inflammatory cells were detected. Images shown are representative of the total and correspond to biopsies
from a non-CF individual (left) and a CF patient (right) performed with jumbo (3.4 mm Ø) forceps after bowel preparation with glycerol (non-CF)
or isotonic saline (CF). In HE-stained sections (top), nuclei are stained in blue and cytoplasm in red. In Tricome’s Masson-stained sections (bottom)
collagen (fibrotic biomarker) is stained in blue, nuclei in black, and muscle and cytoplasm in red. Black scale bar represents 250 μM. B)
Immunohistofluorescence of rectal biopsies showing nuclei in blue (DAPI staining) and CFTR in green. Images evidence CFTR at the membrane in
a non-CF tissue (top panels) and also, albeit weaker, in a biopsy from a CF patient with the F508del/P205S-CFTR genotype (bottom panels). In
contrast, a biopsy from a F508del-homozygous CF patient evidences intracellular CFTR staining (middle panels). A negative control (no primary
antibody n.c.) was also performed. Scale bar represents 25 μm. C) Western blot of a single rectal biopsy from non-CF individuals (wt-CFTR, lanes
1–2) and from a CF patient with F508del/R334W-CFTR genotype (lane 3) evidence the presence of both immature and mature forms of CFTR
(bands B and C, respectively; and from a CF patient with the F508del/F508del-CFTR genotype (lane 4) evidencing only immature form (band B)
which is characteristic of the endoplasmic reticulum (ER) and thus corroborating the traffic defect associated with this mutation.
Table 3 Evaluation of comfort, pain and future repetition of the rectal biopsy procedure assessed by patients by
gender, age group and sedation (n = 75)





















Gender Female 9 20 12 34 7 3 8 6 0 24
Male 9 7 18 25 9 6 6 3 3 16
Age Groups
(years)
0 – 9 7 3 11 15 6 3 2 2 2 12
10 –
19
6 16 11 27 6 5 7 5 1 15
20 –
29
2 3 2 6 1 0 2 1 0 4
≥ 30 3 5 6 11 3 1 3 1 0 9
Sedation No 10 15 12 28 9 6 7 3 1 20
Yes 8 12 18 31 7 3 7 6 2 20
NOTE: Results are n = number of individuals. Statistically significant differences were found between classification of procedure overall comfort regarding
gender (p = 0.032).
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a priori with this procedure (question 6).
Data collected on patients’ (dis)comfort show that 57/
75 (76%) of the interviewed individuals did not report
high levels of discomfort, independently of sedation
or age, but shows statistically significant differences
(p = 0.032) regarding gender (Table 3): as there were
more female patients saying that the overall rectal biopsy
procedure is “somewhat uncomfortable”. Nevertheless,
the majority of both female (32/41) and male (25/34)
reported low levels of discomfort. Also, the great major-
ity of the individuals inquired (78.7%) reported that this
is a painless procedure, regardless of sedation, age or
gender (Table 3). Only 2 individuals assessed the proced-
ure as “Very painful” (data not shown). Moreover the
vast majority of the individuals (88%, 66/75) accepted
repeating this procedure for at least once more (18.7%
for 1 more time; 12% for 2 more times; 4% for 3 more
times; and 53.3% for 4 more times), while only a minor-
ity (12%, 9/75) do not wish to repeat it (Table 3), also
independently of sedation, age and gender.
When asked to indicate which steps of the procedure
they considered as the least/most uncomfortable (Table 4),
data shows that “the monitoring” was considered by the
highest percentage (89.3%) as “Not uncomfortable” (76%)
or “Least uncomfortable” (13.3%), followed by “the
biopsing” (70.7%) and “the bowel preparation” (70.7%),
and finally “the sigmoidoscopy” (66.7%). For the individuals
being sedated, “the sedation” step was also well-tolerated,
as much as “the monitoring step” (Table 4). Furthermore,
as somewhat expected, sedation significantly enhances
the rate of “Not uncomfortable” responses regarding “the
sigmoidoscopy” (p = 0.016) and “the biopsing” (p = 0.003)
procedures. No differences were found regarding gender
or age (Table 4).
Concerning the comparative assessment of the rectal
biopsy procedure with other clinical/diagnosis examina-
tions (Additional file 1: Table S5), most of the individuals
classified the overall rectal biopsy procedure as being “more
unpleasant” than sweat test (76%), followed by spirometry
(64%) and blood collection (53.3%), regardless of gender,
age or sedation. No conclusions could be drawn concerning







NOTE: Results are n = number of individuals. Statistically significant differences were
biopsy (p = 0.003) regarding sedation. n.a. means not applicable.65% of the individuals had not experienced those proce-
dures or were unable to establish a comparison.
Finally, when patients where asked about their pre-
conceptual concerns regarding the procedure (question 6),
the reported answers were similar: 46.7% for preconcep-
tion/taboo and 41.3% for discomfort/pain. The remaining
12% did not answer (data not shown).
Discussion
Measurements of CFTR function in rectal biopsy speci-
mens have proven its value in the fine-diagnosis of
patients with milder or “non-classical” forms of CF, in
particular when sweat test results are equivocal or border-
line and/or if CFTR-disease causing mutations are not
readily identified by DNA mutation analysis [12,14,16]. This
approach also serves as a sensitive test to predict the prog-
nosis when rare CFTR mutations are not identified by
standard screening tests [12,14,16]. Compared to the air-
ways, the rectal epithelium is easily accessible at any age,
expresses higher levels of CFTR, thus increasing robustness
of the measurements and, as shown here (Figure 3-A), does
not undergo major secondary tissue destruction/remodel-
ling as those occurring in CF airways [13].
Moreover, this technique has even potential for a
much wider scope, namely to monitor diseases, affecting
epithelial ion transport [29-31]. Although these studies
were so far only performed in mice, the results are
highly promising for the clinic.
Because functional and biochemical data are not avail-
able for most rare mutations, these specimens can also
be used to establish functional and biochemical correla-
tions with rare CFTR genotypes (Figure 3B, 3C), as also
reported in other studies [12,14,16,28,32,33]. Further-
more, this approach may be used as well to validate effi-
cacy of novel CFTR-modulator compound/drugs directly
on human native tissues for such rare mutations [21-23].
Indeed, rectal biopsies are already in use as outcome
measures in clinical trials for other diseases [24,25] and
for some a high number of biopsies (n = 28) per patient
has been reported without complications [25]. The same
can thus be translated into the CF field.
Since good tissue viability is critical for quantitative as-
sessment of bioelectric responses our recommendation75)






found between classification of comfort for sigmoidoscopy (p = 0.016) and
Servidoni et al. BMC Gastroenterology 2013, 13:91 Page 9 of 12
http://www.biomedcentral.com/1471-230X/13/91is that specimens are maintained in appropriate medium
on ice until used in functional measurements, which
should be performed immediately [13]. To minimize
edge damage (and consequent liquid/electric leakage),
tissues should be mounted under a dissecting micro-
scope for optimal orientation of biopsy on the insert
opening and to prevent tissue damage with excessive
instrument manipulation.
The present study aimed to determine whether and
how bowel preparation for sigmoidoscopy and choice of
biopsy forceps influence tissue viability for subsequent
laboratory analyses, in particular, bioelectric measure-
ments. We compared two commonly used solutions for
bowel preparation at our endoscopy unit, namely gly-
cerol and isotonic saline enema (for sigmoidoscopy) as
well as oral mannitol (for colonoscopy). Our data show
that isotonic saline solution, which we speculate is less
harmful for the mucosa, is superior to glycerol-based
preparation, but there are no significant differences be-
tween NaCl-enema and oral mannitol. Indeed, differ-
ences were detected between mean values for the tissue
integrity parameter between biopsies obtained after
NaCl- and glycerol-based bowel preparations, the former
showing better results (Tables 1 and Additional file 1:
Table S1).
The current study only focuses on the biopsing forceps
procedure, as this is the routine procedure at our endos-
copy unit. Indeed, this is the approach that we regularly
use because it uses an endoscope which allows direct
visual inspection of the mucosa area to be biopsied
during the procedure to avoid hitting on damaged tissue
or any abnormal vascular structures. This reduces the
hemorrhage risk for the patient and increases the safety
profile of the procedure. Indeed, excessive bleeding,
although never occurring in this study, would be rapidly
identified and thus immediately managed. It also allows
avoiding biopsing the same site twice (Additional file 3
video S1: Rectal biopsy procedure).
However, previous [12,13,15,17-19] and recent reports
[14,16,34,35] indicate that biopsies obtained by suction
can be similarly applied (albeit without visual contact)
and major complications have equally not been reported.
In fact, the values for transepithelial resistance found by
ourselves [14] (14–21 Ω × cm2) are comparable with
those found previously using similar (forceps) [12] - 24
Ω × cm2 - or even different (suction) techniques [36,37]:
27 Ω × cm2, and 24–39 Ω × cm2 (no mean values given).
That approach is thus expected to be equally tolerated
by the patients’ while also providing adequate specimens
for electrophysiology studies. Here, we did not compare
suction and forceps biopsy, but just the forceps size
(standard vs jumbo forceps) in terms of how sample size
might affect its viability and also regarding safety of the
procedure. Overall, mean values for tissue integrity(jumbo = 1.07 ± 0.09 vs standard = 2.04 ± 0.18) and also
for Rte (jumbo = 20.97 ± 0.81 Ω.cm
2 vs standard =
14.01 ± 0.86 Ω.cm2) were shown to be statistically
different (p = 5.51x10-7 and p = 8.42x10-8, respectively,
Tables 1, Additional file 1: Table S2), with jumbo
forceps providing the best results.
Importantly, data for both tissue integrity and friability
show good correlations (positive and negative, respect-
ively) with tissue viability (assessed by Rte measure-
ments) and are influenced by bowel preparation and
biopsy forceps (Table 2, Figure 2). Our data also show
that collection of superficial rectal biopsies with (jumbo/
standard) forceps constitutes a safe procedure, as we
observed no complications, similarly to what others
previously reported for studies on Hirschsprung [38] or
inflammatory bowel disease [39].
Data concerning presence/abundance of bleeding and
mucus do not correlate with tissue viability (Rte), but
interestingly there is a trend positive correlation between
mucus and Rte (r = +0.078), indicating that presence of
mucus (i.e. probably resulting from a less “aggressive”
bowel cleaning) could somehow serve to preserve tissue
viability (Table 2 and Figure 2).
Therefore, performing bowel preparation with isotonic
saline and obtaining the rectal biopsies with jumbo for-
ceps are demonstrated to constitute the best combin-
ation for the procedure (Table 1) with the highest mean
values for Rte (21.82 ± 1.03 Ω.cm
2) and the best for
tissue integrity (1.00 ± 0.11). On the other hand, usage of
12% glycerol enema and smaller (standard) forceps pro-
duce the less viable tissues, namely (Table 1): worst tis-
sue integrity (2.21 ± 0.23) and Rte (13.57 ± 2.70 Ω.cm
2),
and highest friability (1.81 ± 0.22), thus rendering quanti-
tative determination of CFTR-mediated Cl- secretion less
reliable. It is likely that usage of the glycerol-based
enema, acting as an osmotic laxative and thus increasing
the luminal volume, which stretches the mucosa, makes
it more susceptible to friability and disruption, com-
promising tissue integrity. Alternative for bowel preparation
in children could be sodium citrate + sodium lauryl
sulfoacetate, together with glycerol + sorbitol (“Microlax®”)
or dioctyl sulfosuccinic acid sodium salt + sorbitol (“Clyss-
go®”), which we had previously experienced to yield viable
specimens if done the day before sigmoidoscopy (data not
shown), probably allowing rectal mucosa to recover from
this enema procedure. However, as these procedures were
not rigorously assessed, we cannot compare them we the
ones used in the present study.
The easy access to the patients rectum and the low
innervation of this area minimizing pain, makes this ap-
proach to be expectedly well tolerated [12,14]. Moreover,
modern gastroenterology techniques and instruments
currently applied in outcome measures for clinical trials
have made this approach increasingly simpler and easier
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sigmoidoscopy/rectal biopsy procedure, sedation was
used primarily to reduce anxiety and ensure cooperation
(only for 24% of the sigmoidoscopy/rectal biopsy cases
sedation was preferred, see Methods), especially in small
children that generally demonstrate less cooperation in
any medical procedure In cooperative, non-anxious
patients, our experience recommends that the procedure
is performed with no anaesthesia.
Regarding safety of the patients, one CF patient who
complained of abdominal pain (see Results) was the only
patient with inappropriate bowel cleaning, where more
insufflation had to be used in order to carry out the pro-
cedure. This patient also had a clinical history of surgical
interventions for meconium ileus and colonic adhesions,
which might be related to the abdominal pain. We also
report minor complications that cannot be fully related to
the sigmoidoscopy procedure: one patient who vomited
(although his parents informed that this usually happens
when he fasts) and another patient who underwent both
upper endoscopy and sigmoidoscopy also reported pain,
but it is likely that the former procedure was the
source of pain.
Thus, the present study also shows that this procedure
with jumbo forceps is safe to be applied from young
children to adults (age range was 6 months to 52 years),
which application is relevant also for other disorders as
Hirschsprung or inflammatory bowel disease. Although
we have no experience, it also expected that it can be
safely applied to newborns, namely those identified in
increasing numbers as asymptomatic CF patients by the
recently implemented extensive newborn screening pro-
grams, merely based on elevated serum concentrations
of immunoreactive trypsinogen (IRT). Indeed, these pa-
tients, posing new challenges to the CF diagnosis and
prognosis are likely candidates to undergo this proced-
ure to find evidence of CFTR (dys)function.
One of the major limitations usually related to patient
surveys, is that we can only rely on the responses of the
individuals who agree to undergo certain procedures. In
this case, we are relying on the perspectives of the pa-
tients who agreed to participate on the sigmoidoscopy/
rectal biopsy procedure, so there is a selection bias that
leads to underscoring the fraction of individuals who do
not tolerate this kind of procedure. Nevertheless, we can
only rely on the responses of the individuals who agreed
to participate, as those who have not undergone the
procedure can only have preconceptions and not real
experience to assess it. Importantly, patient enquiries
demonstrate that for the majority of the individuals
(76%) the rectal biopsy procedure is not associated with
high levels of discomfort due to the short procedure
time (max 15 min, Additional file 3 Video S1: Rectal bi-
opsy procedure), regardless of sedation (Table 3) and nosignificant differences were found between the “control
group” – with an already established CF diagnosis- and
the “diagnostic group” (data not shown). Moreover, this
shows to be also a relatively painless procedure, as 79%
of the individuals did not report pain (Table 3). Never-
theless, “the sigmoidoscopy step” was associated with
the highest level of discomfort (Table 4) as possibly
expected, probably because of the preconceptions associ-
ated with this type of procedure. Accordingly, the indi-
viduals interviewed classified the rectal biopsy procedure
as more unpleasant than sweat test, spirometry or blood
collection (Additional file 1: Table S5). But if these indi-
viduals are required to repeat the biopsy procedure, des-
pite some preconception concerns comprising prejudice
and discomfort, the great majority (88%) would accept
doing it for at least one more time, with 53.3% of the pa-
tients accepting to repeat it up to four more times
(Table 3). Importantly, we also have to take into account,
especially when a research procedure which is not rou-
tine is attempted, that adults above 20 years of age are
more receptive to repeat the procedure than adolescents
or children (as reported by their parents).
Conclusions
In conclusion, results from the present study recom-
mend that in the case of forceps biopsy, rectal biopsies
should be obtained with jumbo biopsy forceps after
bowel preparation with NaCl isotonic solution to obtain
viable specimens for bioelectric measurements for CF
studies. The procedure is safe and is well tolerated from
the patients’ perspective, demonstrating its feasibility as
an outcome measure in clinical trials.
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